A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bendamustine Hydrochloride
/ administration & dosage
Bortezomib
/ administration & dosage
Dexamethasone
/ administration & dosage
Disease-Free Survival
Female
Humans
Lymphoma, Mantle-Cell
/ drug therapy
Male
Middle Aged
Rituximab
/ administration & dosage
Survival Rate
Time Factors
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
23
02
2018
accepted:
23
08
2018
pubmed:
2
9
2018
medline:
30
4
2020
entrez:
2
9
2018
Statut:
ppublish
Résumé
We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrolled (median age, 73 years). Patients received a maximum of six cycles of treatment at 28-day intervals. The primary objective was to achieve an 18-month progression-free survival rate of 65% or higher. Secondary objectives were to evaluate toxicity and the prognostic impact of mantle cell lymphoma prognostic index, Ki67 expression, [
Identifiants
pubmed: 30171024
pii: haematol.2018.191429
doi: 10.3324/haematol.2018.191429
pmc: PMC6312036
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-146Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Blood Adv. 2018 Apr 10;2(7):807-816
pubmed: 29636326
Blood. 2015 Jan 1;125(1):48-55
pubmed: 25499451
Leuk Lymphoma. 2009 Aug;50(8):1257-60
pubmed: 19544140
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
Ann Oncol. 2012 Jun;23(6):1555-61
pubmed: 22012966
J Clin Oncol. 2002 Mar 1;20(5):1288-94
pubmed: 11870171
J Clin Oncol. 2005 May 20;23(15):3383-9
pubmed: 15908650
J Clin Oncol. 2008 Sep 20;26(27):4473-9
pubmed: 18626004
Blood. 2016 Oct 6;128(14):1814-1820
pubmed: 27354719
Br J Haematol. 2012 Aug;158(3):355-62
pubmed: 22640180
Lancet. 2016 Aug 6;388(10044):565-75
pubmed: 27313086
J Clin Oncol. 2005 Mar 20;23(9):1984-92
pubmed: 15668467
Clin Cancer Res. 2016 Sep 1;22(17):4350-4355
pubmed: 27060151
Lancet Haematol. 2017 Jan;4(1):e15-e23
pubmed: 27927586
Blood. 2017 Jul 27;130(4):440-452
pubmed: 28600337
N Engl J Med. 2012 Aug 9;367(6):520-31
pubmed: 22873532
N Engl J Med. 2015 Mar 5;372(10):944-53
pubmed: 25738670
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42
pubmed: 20428863
Br J Haematol. 2012 Jul;158(2):186-197
pubmed: 22626453
Lancet Oncol. 2011 May;12(5):431-40
pubmed: 21507715
Sci Transl Med. 2016 Nov 9;8(364):364ra155
pubmed: 27831904
Methods Mol Biol. 2018;1768:229-256
pubmed: 29717447
Haematologica. 2016 Mar;101(3):336-45
pubmed: 26703963
N Engl J Med. 2017 Sep 28;377(13):1250-1260
pubmed: 28953447
J Hematop. 2009 Jul;2(2):103-11
pubmed: 19669190
Expert Rev Mol Diagn. 2017 Jun;17(6):557-566
pubmed: 28415895
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
Blood. 2006 Mar 15;107(6):2271-8
pubmed: 16332971
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
Nat Med. 2014 Dec;20(12):1401-9
pubmed: 25419709
Blood. 2010 Apr 22;115(16):3215-23
pubmed: 20032498
Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435
pubmed: 28039078
Blood. 2011 Mar 10;117(10):2807-12
pubmed: 21239695
Ann Oncol. 2009 Mar;20(3):520-5
pubmed: 19074748
J Clin Oncol. 2009 Sep 10;27(26):4365-70
pubmed: 19652064
Nat Rev Cancer. 2018 Apr;18(4):255-263
pubmed: 29376520
J Clin Oncol. 2013 Apr 10;31(11):1442-9
pubmed: 23401442